Company news
Werewolf Therapeutics, Inc. news in 2023
Werewolf Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.
Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
November 13, 2023
Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
November 2, 2023
Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
September 26, 2023
Werewolf Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
August 9, 2023
Werewolf Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
May 10, 2023
Werewolf Therapeutics Publishes Preclinical Data on mWTX-330, an IL-12 INDUKINE™ Molecule, in Cancer Immunology Research
April 18, 2023
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 22, 2023
UPDATE -- Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2023
March 15, 2023
Werewolf Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2023
March 14, 2023
Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1 Study of WTX-330
February 23, 2023
Decks in 2023
- Technical Presentation (November 2023)
Technical · 15 slides · Nov 3, 2023
- Investor Presentation (September 2023)
Investor deck · 22 slides · Sep 18, 2023